Mira Pharmaceuticals Azioni (NASDAQ: MIRA)

Ultime notizie per Mira Pharmaceuticals (NASDAQ:MIRA) Azioni

Mira Pharmaceuticals

Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals Inc

MIRAI Corp

MIRAIT One Corp

MIRAMAR RESOURCES LTD by MIRAMAR RESOURCES LTD

MIRATI THERAPEUTICS INC COM

MIRACLE ENTMT INC by Miracle Entertainment Inc.

Miracle Entertainment Inc

MIRAGE ENERGY CORP by Mirage Energy Corporation

Mirage Energy Corp

MIRAMAR HOTE & INVST CO by Miramar Hotel & Investment Co., Ltd.

Miramar Hotel & Investment Co Ltd

TAKARA LEBEN CO LTD by Takara Leben Co., Ltd.

Mirarth Holdings Inc

MIRASOL RESOURCES LTD by Mirasol Resources Ltd.

Mirasol Resources Ltd

Miratap Inc

MIRAVANT MEDICAL TECHS by Miravant Medical Technologies

Miravant Medical Technologies

The CNN Money Fear and Greed index showed a slight decline in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Tuesday.
U.S. stocks settled lower on Tuesday, with the Dow Jones index falling more than 100 points during the session. The S&amp;P 500 also snapped a six-session winning streak.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) stock edged higher on Tuesday after CEO Elon Musk, speaking at the Qatar Economic Forum, said he remains committed to leading the company for the next five years.
Home Depot Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) reported stronger-than-expected first-quarter sales results and reaffirmed its full-year outlook. Amer Sports, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AS#NYSE">AS</a>) reported better-than-expected first-quarter FY25 results.
On the economic data front, the U.S. Redbook Index rose by 5.4% year-over-year in the week ending May 17.
Most sectors on the S&amp;P 500 closed on a negative note, with energy, consumer discretionary, and communication services stocks recording the biggest losses on Tuesday. However, utilities and health care stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 115 points to 42,677.24 on Tuesday. The S&amp;P 500 fell 0.39% to 5,940.46, while the Nasdaq Composite declined 0.38% to 19,142.71 during Tuesday's session.
Investors are awaiting earnings results from Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>), Lowe&#8217;s Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>), and The TJX Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 69.2, the index remained in the &#8220;Greed&#8221; zone on Tuesday, versus a prior reading of 69.4.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/05/45517463/top-2-risk-off-stocks-that-are-ticking-portfolio-bombs">Top 2 Risk Off Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo courtesy: Shutterstock

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

TSLA

S&P 500 Snaps 6-Session Winning Streak: Investor Sentiment Edges Lower, But Fear Index Remains In 'Greed' Zone

V.F. Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) will release its fourth-quarter earnings results before the <a href="https://www.benzinga.com/quote/VFC/earnings">opening bell on Wednesday, May 21</a>.
Analysts expect the Denver, Colorado-based company to report a quarterly loss at 14 cents per share, versus a year-ago loss of 32 cents per share in the year-ago period. According to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>, V.F. Corporation projects to report quarterly revenue at $2.17 billion, compared to $2.37 billion a year earlier.
On Jan. 29, the company reported third-quarter sales of $2.834 billion, beating the analyst consensus estimate of $2.746 billion.
V.F. Corporation shares gained 0.8% to close at $14.43 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/vfc/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>JP Morgan analyst Matthew Boss maintained a Neutral rating and cut the price target from $25 to $18 on May 19, 2025. This analyst has an accuracy rate of 68%.</li>
<li>UBS analyst Jay Sole maintained a Neutral rating and raised the price target from $12 to $16 on May 19, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Wells Fargo analyst Ike Boruchow maintained an Equal-Weight rating and increased the price target from $12 to $13 on May 14, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating and cut the price target from $27 to $17 on May 14, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Barclays analyst Adrienne Yih maintained an Overweight rating and slashed the price target from $34 to $19 on May 12, 2025. This analyst has an accuracy rate of 66%</li>
</ul>
Considering buying VFC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="611" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21024707/image-253-1024x611.png" alt="" class="wp-image-922238" style="width:613px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21024707/image-253-1024x611.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21024707/image-253-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21024707/image-253-768x458.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21024707/image-253.png 1101w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/05/45517463/top-2-risk-off-stocks-that-are-ticking-portfolio-bombs">Top 2 Risk Off Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Price Target

Analyst Ratings

Top Wall Street Forecasters Revamp VF Corporation Expectations Ahead Of Q4 Earnings

CIFR

Reported Earlier, Cipher Mining Sets $150M Senior Notes at 1.75% Interest With Option for Cash or Stock Conversion, Maturity in 2030

The TJX Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) will release its first-quarter earnings results before the opening <a href="https://www.benzinga.com/quote/tjx/earnings">bell on Wednesday, May 21.</a>
Analysts expect the Framingham, Massachusetts-based company to report quarterly earnings at 91 cents per share. That's down from 93 cents per share in the year-ago period. According to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>, TJX projects to report quarterly revenue at $13.03 billion, compared to $12.48 billion a year earlier.
On Feb. 26, the company reported that its fourth-quarter FY25 sales remained flat year-on-year to $16.4 billion, beating the analyst consensus estimate of $16.20 billion.
TJX shares fell 0.1% to close at $134.93 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/GBX/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>TD Securities analyst John Kernan maintained a Buy rating and raised the price target from $140 to $142 on May 20, 2025. This analyst has an accuracy rate of 70%.</li>
<li>JP Morgan analyst Matthew Boss maintained an Overweight rating and raised the price target from $127 to $130 on May 19, 2025. This analyst has an accuracy rate of 68%.</li>
<li>Wells Fargo analyst Ike Boruchow maintained an Equal-Weight rating and increased the price target from $115 to $120 on May 14, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Citigroup analyst Paul Lejuez upgraded the stock from Neutral to Buy and raised the price target from $128 to $140 on April 3, 2025. This analyst has an accuracy rate of 65%.</li>
<li>BMO Capital analyst Simeon Siegel maintained an Outperform rating and increased the price target from $133 to $145 on Feb. 27, 2025. This analyst has an accuracy rate of 75%</li>
</ul>
Considering buying TJX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="594" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21023640/image-252-1024x594.png" alt="" class="wp-image-922221" style="width:669px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21023640/image-252-1024x594.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21023640/image-252-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21023640/image-252-768x446.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21023640/image-252.png 1122w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/05/45517463/top-2-risk-off-stocks-that-are-ticking-portfolio-bombs">Top 2 Risk Off Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

TJX Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Economist Justin Wolfers is once again directing criticism at President Donald Trump, this time taking aim at the administration's sweeping tax and spending bill, which Trump has described as &#8220;one big, beautiful bill.&#8221;
What Happened: Speaking on the TheRickWilson podcast on Tuesday, Wolfers said the current budget being debated includes deep cuts to social safety nets like Medicare and Medicaid, while preserving or expanding benefits for the ultra-wealthy.
&#8220;This one seems to bundle up a whole bunch of things that are going to cause social cost and economic cost to a lot of people,&#8221; he says, adding that it is &#8220;stacked towards the upper end of the upper end of the upper end of the economic food chain.&#8221;
See Also: <a href="https://www.benzinga.com/25/05/45533526/trumps-no-tax-on-tips-agenda-gets-a-boost-as-senate-approves-bill-ted-cruz-praises-presidents-political-genius-for-backing-the-idea">Trump&#8217;s No Tax On Tips Agenda Gets A Boost As Senate Approves Bill, Ted Cruz Praises President&#8217;s &#8216;Political Genius&#8217; For Backing The Idea</a>
The University of Michigan professor later emphasized the kind of impact this type of fiscal policy will have on everyday Americans. &#8220;If you drove yourself to work, you're one of the people who's probably going to get less out of this,&#8221; he said. &#8220;It's just pure reverse Robin Hood.&#8221;
Wolfers argues that budgets aren&#8217;t just economic plans, but rather a &#8220;statement of values&#8221; and ultimately a &#8220;moral statement.&#8221; Referring to the cuts made to Medicare and Medicaid, he says, &#8220;If your values are that you don't want to make sure poor people have health insurance, that's your statement.&#8221;
The economist also warned that the budget's structure could validate recent concerns about U.S. creditworthiness, pointing to <a href="https://www.benzinga.com/markets/25/05/45484954/treasury-secretary-bessent-addresses-moodys-downgrade-and-tariff-impact-n-walmart">Moody's downgrade</a> as a rational response to persistent fiscal instability. 
Rising bond yields will increase borrowing costs significantly, Wolfers says, &#8220;a small percent times a humongous number is a very large number.&#8221;
Why It Matters: Other prominent economists have since weighed in on this bill, echoing similar views. Craig Shapiro posted on X, saying that the bill &#8220;will explode the deficit while enriching the highest decile of Americans at the expense of the lowest decile.&#8221;
&#8220;Another opportunity squandered and further proof that the Republican Party continues to cater to the wealthiest Americans time and time again,&#8221; he says.
<figure class="wp-block-embed aligncenter is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Nice job by the Admin and House Republicans getting ready to try to pass a &quot;Big Beautiful Bill&quot; that will explode the deficit while enriching the highest decile of Americans at the expense of the lowest decile. Another opportunity squandered and further proof that the… <a href="https://t.co/66cJwNwE8m">https://t.co/66cJwNwE8m</a>
&mdash; Craig Shapiro (@ces921) <a href="https://twitter.com/ces921/status/1925005561180942458?ref_src=twsrc%5Etfw">May 21, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Sen.&nbsp;Elizabeth Warren&nbsp;(D-Mass.) and Senator&nbsp;Bernie Sanders&nbsp;(I-Vt), alongside several other Democratic leaders, have <a href="https://www.benzinga.com/25/05/45511553/elizabeth-warren-slams-republicans-for-dead-of-night-voting-strategy-on-trumps-big-beautiful-billwhy-hide">denounced the bill</a>, Sanders calling it a "death sentence" for millions of Americans, while offering $235 billion in tax breaks for the wealthiest 0.2%.
According to the Congressional Budget Office (CBO), changes to Medicaid could leave <a href="https://benzinga.com/general/health-care/25/05/45345409/trumps-big-beautiful-bill-banks-on-huge-medicaid-cuts-as-its-cost-saving-centerpiece-see-who-risks-losing-coverage-under-the-gop-proposal">8.6 million people uninsured</a> within a decade. The Democrats have since called it a fresh attempt by the GOP to gut the Affordable Care Act.
The bill does include some provisions Trump campaigned on, such as eliminating <a href="https://www.benzinga.com/25/05/45533526/trumps-no-tax-on-tips-agenda-gets-a-boost-as-senate-approves-bill-ted-cruz-praises-presidents-political-genius-for-backing-the-idea">federal taxes on tips and overtime</a> pay, which is finding support.
Photo Courtesy: Joshua Sukoff On Shutterstock.com
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45534539/social-security-full-retirement-age-shift-means-filing-at-62-could-chop-your-check-by-30-what-every-worker-born-in-1960-or-later-must-know">Social Security Full Retirement Age Shift Could See Your Check Chopped By 30% — What Everyone Born In 1960 Or Later Must Know</a></li>
</ul>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Live with Justin Wolfers" width="500" height="281" src="https://www.youtube.com/embed/lwMz0NOa3fo?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>

Government

Trump's 'One Big, Beautiful Bill' Slammed As 'Reverse Robin Hood' By Economist Justin Wolfers — Takes From The Poor, To Give To The Rich

LAES

WKEY

WISeKey Unveils WISe.ART 3.0: A Secure, Intelligent Web3 Marketplace Linking Digital Twins To Physical Artifacts

Cool Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLCO#NYSE">CLCO</a>) reported quarterly sales of $85.55 million which beat the analyst consensus estimate of $81.67 million by 4.75 percent. This is a 2.70 percent increase over sales of $83.30 million the same period last year.

CLCO

Cool Co Q1 Sales $85.55M Beat $81.67M Estimate, Net Income $9.1M Down From $29.4M YoY

With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
<ul class="wp-block-list">
<li>Wall Street expects Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) to report quarterly earnings at $1.65 per share on revenue of $24.32 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Target shares slipped 0.01% to $98.11 in after-hours trading.</li>
<li>Palo Alto Networks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) posted better-than-expected earnings for its third quarter on Tuesday. The company also raised its full-year 2025 guidance. The company now expects full-year revenue of $9.17 billion to $9.19 billion, up from prior guidance of $9.14 billion to $9.19 billion. The company now anticipates full-year adjusted earnings of $3.26 to $3.28 per share, up from prior guidance of $3.18 to $3.24 per share, per Benzinga Pro. Palo Alto shares fell 3.9% to $186.92 in the after-hours trading session.</li>
<li>Analysts are expecting Lowe&#8217;s Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) to post quarterly earnings at $2.88 per share on revenue of $20.96 billion. The company will release earnings before the markets open. Lowe&#8217;s shares rose 0.1% to $231.50 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul class="wp-block-list">
<li>Toll Brothers, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) posted stronger-than-expected earnings and sales results for the second quarter. The company reported quarterly earnings of $3.50 per share, which beat the analyst consensus estimate of $2.92 by 19.86%. Quarterly revenue came in at $2.71 billion, which beat the Street estimate of $2.48 billion. Toll Brothers shares climbed 5.1% to $109.81 in the after-hours trading session.</li>
<li>Analysts expect The TJX Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) to report quarterly earnings at 90 cents per share on revenue of $12.99 billion before the opening bell. TJX shares fell 0.3% to $134.50 in after-hours trading.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/05/45517463/top-2-risk-off-stocks-that-are-ticking-portfolio-bombs">Top 2 Risk Off Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

PANW

Target, Lowe's And 3 Stocks To Watch Heading Into Wednesday

ALGT

Allegiant Announces Five New Nonstop Routes With One-Way Fares Starting At $39 To Underserved Cities Across Eight Markets

Golden Ocean Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOGL#NASDAQ">GOGL</a>) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.16) by 18.75 percent. This is a 165.52 percent decrease over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $141.93 million which beat the analyst consensus estimate of $119.25 million by 19.02 percent. This is a 42.48 percent decrease over sales of $246.74 million the same period last year.

Earnings Beats

Earnings Misses

GOGL

Golden Ocean Group Q1 Adj. EPS $(0.19) Misses $(0.16) Estimate, Sales $141.93M Beat $119.25M Estimate

Macro Economic Events

Econ #s

Economics

U.K. Consumer Price Index (YoY) For April 3.5% Vs. 3.3% Est.; 2.6% Prior

U.K. Consumer Price Index (MoM) For April 1.2% Vs. 1.1% Est.; 0.3% Prior

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk believes Tesla owners would be able to add their vehicles to the company's fleet of self-driving cars, as he says no to any potential deal with Uber Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>).
What Happened: "We have millions of cars that will be able to operate autonomously. And I should say that it&#8217;s a combination of a Tesla-owned fleet and also enabling Tesla owners to be able to add or subtract their car to the fleet," Musk said in an <a href="https://www.cnbc.com/video/2025/05/20/tesla-ceo-elon-musk-theres-no-need-for-tesla-to-buy-uber.html">interview</a> with CNBC's David Faber.
Musk believes that it could be a mix of Uber and Airbnb Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>), where Tesla owners could add their cars to the autonomous fleet and earn money.
"Tesla has all the ingredients necessary to offer a vast self-driving fleet, overnight," Musk said in the interview, reiterating the company's FSD technology's capabilities.
Why It Matters: The interview and Musk's comments outlined the billionaire's vision for the company's future, which focuses heavily on FSD and autonomous driving.
Musk also shared that next month's <a href="https://www.benzinga.com/25/05/45529030/elon-musk-confirms-tesla-robotaxi-launch-is-on-track-for-next-month-these-things-happen-slowly-but-then-all-at-once">Robotaxi launch in Austin</a> is going ahead as planned and could be ramped up to over 1,000 vehicles within the next few months and hundreds of thousands by the end of next year, "if not a million," he said.
Elsewhere, Uber CEO Dara Khosrowshahi <a href="https://www.benzinga.com/25/05/45467794/uber-ceo-dara-khosrowshahi-says-he-isnt-worried-about-teslas-robotaxis-transportation-is-a-trillion-plus-dollar-industry">brushed off any concerns </a>about Tesla&#8217;s autonomous driving capabilities. &#8220;You could argue that rideshare is going to finally beat personal car ownership in a world where you've got robots driving all over the place,&#8221; he said, and suggested there wasn&#8217;t a single big winner.
<a href="https://www.benzinga.com/news/25/05/45519469/tesla-stock-rises-after-musk-reaffirms-leadership-and-business-rebound">Tesla's stock surged </a>over 3.54% as Musk reaffirmed his commitment to Tesla and pledged to remain CEO for the next five years. New insured registration data from China also indicates <a href="https://www.benzinga.com/25/05/45513708/tesla-new-vehicle-registrations-surge-in-china-gary-black-says-it-should-provide-investors-some-relief">an uptick in sales </a>for the EV giant, which was at 11,130 registrations for the week of 12-18 May 2025, a stark increase from a little over 3,000 registrations the week prior.
Price Action: TSLA gained 0.51% at close and currently trades for $343.82, according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro data</a>.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/05/45512512/tesla-robotaxi-rival-waymo-announces-california-expansion-as-autonomous-taxi-race-heats-up">Tesla Robotaxi Rival Waymo Announces California Expansion As Autonomous Taxi Race Heats Up</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

ABNB

UBER

Elon Musk Brushes Off Potential Tesla-Uber Deal, Believes Owners Could Add Their Cars To EV Giant's Autonomous Fleet Instead

Guidance

Wix Projects Q2 Revenue Growth Of 11–12%, Forecasting $485M–$489M Vs. $490.53M Est.

Increase to Share Repurchase Program
Wix's Board of Directors has authorized an increase to its program to repurchase the Company's securities (ordinary shares and/or convertible notes) by an additional amount of up to $200 million, on top of the $200 million previously approved by the Board on February 26th, 2025 (which has not been used to date). This approval brings the repurchase authorization under the program to a total amount of up to $400 million.

Buybacks

Wix Board Approves Additional $200M For Share And Convertible Note Buybacks, Bringing Total Authorization To $400M

Financial Outlook
Healthy first quarter results demonstrate impactful product innovation and disciplined execution of our key growth initiatives, including Studio, AI and our focus empowering Self Creators. Notably, new cohort strength remains robust through April and early May against a dynamic macro backdrop. We expect new cohort strength to continue and drive top-line growth acceleration in 2H as additional cohorts layer on throughout the year.
While we are encouraged by our strong Q1 results and robust top of funnel, we are maintaining full year bookings outlook of $2,025 - 2,060 million, up 11-13% y/y. This reflects conservatism due to macro uncertainty, specifically in our Business Solutions segment, with potential volatility offset by fully dissipating FX headwinds.
With these same considerations, we are also maintaining our full year revenue outlook of $1,970 - 2,000 million, up 12-14% y/y.
We expect total revenue in Q2 2025 to be $485 - 489 million, up 11-12% y/y.
For the full year 2025, we continue to expect non-GAAP total gross margin of ~70% and non-GAAP operating expenses to be 47-48% of revenue for the full year.
We continue to expect to generate free cash flow of $590 - 610 million, or ~30-31% of revenue.
As a result, we remain on track to achieve Rule of 45 in 2025 at the high end of our outlook.

Wix Maintains FY25 Revenue Outlook Of $1.97B–$2.00B Vs. $2.02B Est. And Bookings Of $2.025B–$2.06B, Expects Top-Line Acceleration In 2H On Cohort Growth

JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) CEO Jamie Dimon, who correctly flagged trouble before the 2008 Lehman Brothers collapse, is now cautioning that Wall Street&#8217;s expectations for S&amp;P 500, tracked by SPDR S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) earnings growth could plummet from 12% to 0% as tariff impacts ripple through the economy.
What Happened: &#8220;I think earnings estimates will come down, which means PE [Price-to-Earnings&nbsp;ratio] will come down,&#8221; Dimon said at the bank&#8217;s annual investor day, suggesting equity valuations face downward pressure. He described current asset prices as &#8220;kind of high&#8221; while credit spreads remain &#8220;kind of low.&#8221;
Hedge fund manager Dan Niles highlighted Dimon&#8217;s track record on X, noting, &#8220;Dimon warned of an economic &#8216;hurricane&#8217; in June of 2022 before the banking crisis in March of 2023.&#8221; Niles emphasized JPMorgan&#8217;s unique perspective, writing, &#8220;With $4.4 trillion in assets, JPM has more granular data on the health of the U.S. economy than almost anyone.&#8221;
&#8220;I continue to believe that the holidays will be a much rougher time for markets,&#8221; Niles wrote. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Yesterday, <a href="https://twitter.com/search?q=%24JPM&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$JPM</a> CEO Jamie Dimon said he believes Wall Street estimates for S&amp;P earnings growth will go to 0% from 12% to start the year as the impact of tariffs work through the economy "which means PE will come down." He also said asset prices are "kind of high" and credit…
&mdash; Dan Niles (@DanielTNiles) <a href="https://twitter.com/DanielTNiles/status/1924902062283784681?ref_src=twsrc%5Etfw">May 20, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Next: <a href="https://www.benzinga.com/25/05/45534527/china-warns-of-legal-retaliation-against-us-chip-sanctions-threatens-lawsuits-for-aiding-discriminatory-tech-crackdown">China Warns Of Legal Retaliation Against US Chip Sanctions, Threatens Lawsuits For Aiding &#8216;Discriminatory&#8217; Tech Crackdown</a>
Why It Matters: Dimon&#8217;s concerns extend beyond earnings, as he warned of &#8220;huge deficits&#8221; and &#8220;almost complacent central banks.&#8221; He believes markets display &#8220;an extraordinary amount of complacency&#8221; despite <a href="https://www.benzinga.com/news/management/25/05/45508514/jpmorgan-ceo-jamie-dimon-warns-huge-deficits-complacent-central-banks-could-lead-to-stagflation">mounting risks from tariffs and geopolitical tensions</a>, putting the odds of stagflation at &#8220;roughly double&#8221; what markets anticipate.
Despite these warnings, Goldman Sachs recently raised its S&amp;P 500 12-month target to 6,500 while reducing recession odds to 35%, citing the Trump administration&#8217;s decision to <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45379707/sp-500-to-6500-goldman-sachs-trims-recession-odds-as-trump-backs-off-on-tariffs">pause retaliatory tariffs for 90 days</a>.
JPMorgan&#8217;s chief global strategist, David Kelly, maintains the U.S. economy will likely avoid recession but expects slower growth due to tariffs and other economic factors <a href="https://www.benzinga.com/markets/25/05/45485111/jpmorgan-chase-us-economy-likely-to-skirt-recession-forecasts-sluggish-growth">potentially squeezing consumer spending</a>.
Since taking the helm in 2005, Dimon has led JPMorgan to a total return of 1,012%, including dividends, surpassing the S&amp;P 500's 596% gain and even outpacing the Nasdaq's 971% rise.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45534622/sergey-brin-comes-out-of-retirement-to-work-on-gemini-admits-he-made-a-lot-of-mistakes-with-google-glass-as-the-tech-giant-ramps-up-efforts-to-compete-with-meta-and-apple">Sergey Brin Comes Out Of Retirement To Work On Gemini, Admits He Made A &#8216;Lot Of Mistakes&#8217; With Google Glass As Alphabet Ramps Up To Compete With Meta And Apple</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: lev radin / Shutterstock.com

Equities

Jamie Dimon, Who Flagged Trouble Before 2008 Lehman Brothers Collapse, Now Warns S&P Earnings Could Fall To 0%: 'Rougher Time For Markets,' Says Dan Niles

BBJP

WisdomTree Trust Japan Total Dividend Fund

Reported Earlier, Japan Trade Balance For April -115.8B Vs. 227.1B Est.; 559.4B Prior

Reported Earlier, Japan Exports (YoY) For April 2.0% Vs. 2.0% Est.; 4.0% (Revised) Prior

Reported Earlier, Japan Adjusted Trade Balance -0.41T Vs. -0.24T Est.; -0.29T (Revised) Prior

Press Releases

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity

MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review

MIRA

AN2 Therapeutics

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Aytu BioPharma

CalciMedica

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cingulate

Cocrystal Pharma

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Durect

Gelteq

Grace Therapeutics

IGC Pharma

Iterum Therapeutics

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Lexaria Bioscience

Lipocine

Pulmatrix

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Scilex Holding

SCYNEXIS

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

TherapeuticsMD

VYNE Therapeutics

Rodman & Renshaw

Ascendiant Capital

Screenshot 2024-10-02 at 5.44.40 PM

Biotech

General

Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game

Screenshot 2024-09-18 at 6.27.57 PM

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025

Screenshot 2024-09-04 at 6.19.41 PM

TELO

Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs

Screenshot 2024-08-26 at 4.53.37 PM

The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End

Screenshot 2024-07-25 at 6.08.16 PM

MIRA Pharmaceuticals (NASDAQ: MIRA) Reports Promising Pre-Clinical Trial Results For Mental Health Treatment, To Submit Investigational New Drug Application By End Of Year

Comments

Mira Pharmaceuticals

Notizie

Ultime notizie per Mira Pharmaceuticals (NASDAQ:MIRA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO